Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE:PRX) , today announced that the U.S. FDA has accepted the new drug application (NDA) for miconazole Lauriad mucoadhesive buccal tablets (MBT) to treat oropharyngeal candidiasis (OPC).
The details can be read here.
No comments:
Post a Comment